Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (Xtandi®) Alone in Prostate Cancer Models PR Newswire (Press Release) 14:17 Mon, 17 Aug
